European Commission expands use of Crizotinib

Around 12-2-2015 the Europe Commission approved Xalkori (Crizotinib) as a first line treatment so it can be given before chemotherapy.

This entry was posted in crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply